Biolexis Therapeutics Inc. has identified glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of diabetes, obesity, stroke, myocardial infarction, renal failure, chronic kidney disease, Alzheimer’s disease and metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD).

Alexion Pharmaceuticals Inc. has reported complement C1s subcomponent (C1S) inhibitors. They are described as potentially useful for the treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, lupus nephritis and more.

RS Oncology LLC has disclosed thiostrepton derivatives. They are reported to be useful for the treatment of cancer.

Gan & Lee Pharmaceuticals Co. Ltd. has prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an estrogen receptor α(ER-α; ESR1) targeting moiety via a linker reported to be useful for the treatment of cancer.

Chengdu Zeling Biomedical Technology Co. Ltd. has patented receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, atherosclerosis, cancer, sepsis, diabetes, nephritis, multiple sclerosis and Alzheimer’s disease.

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have defined cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of chronic kidney disease, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome as well as kidney and myocardial fibrosis.

Biolexis Therapeutics Inc. has identified AMP-activated protein kinase (AMPK) activators reported to be useful for the treatment of diabetes, ischemia-reperfusion injury, dyslipidemia, obesity, Duchenne muscular dystrophy, metabolic dysfunction-associated steatotic liver disease, spinal muscular atrophy and Alzheimer's disease, among others.

Neurocrine Biosciences Inc. has disclosed chemically modified polypeptides acting as gastric inhibitory polypeptide receptor (GIPR) and/or glucagon receptor (GCGR) and/or glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of obesity.

Eli Lilly & Co. has disclosed new glucose-dependent insulinotropic receptor (GDIR; GPR119) agonists reported to be useful for the treatment of obesity and type 2 diabetes.

Poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors have been described in a Protheragen Inc. patent as potentially useful for the treatment of cancer, neurodegeneration, cardiovascular disorders, metabolic and autoimmune diseases.